Table 3.
Multivariable adjusted1 OR and 95% CI for invasive breast cancer defined by combinations of biomarkers with lifetime recreational physical activity
| Cases sub-grouped by ER/HER2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Average exercise activity (annual MET h/week) | No. of controls | No. of cases | OR (95% CI) | No of cases | OR (95% CI) | No. of cases | OR (95% CI) | No. of cases | OR (95% CI) |
| Cases sub-grouped by ER/HER2 status | |||||||||
| ER−/HER2− | ER−/HER2+ | ER+/HER2− | ER+/HER2+ | ||||||
| Inactive | 500 | 106 | Referent | 30 | Referent | 152 | Referent | 19 | Referent |
| ≤2.2 | 373 | 59 | 0.76 (0.53–1.08) | 17 | 0.86 (0.46–1.60) | 110 | 0.88 (0.66–1.17) | 22 | 1.52 (0.80–2.89) |
| 2.3–6.6 | 369 | 78 | 0.97 (0.70–1.36) | 24 | 1.18 (0.66–2.09) | 123 | 0.95 (0.71–1.26) | 25 | 1.67 (0.89–3.16) |
| 6.7–15.1 | 374 | 66 | 0.77 (0.54–1.10) | 22 | 1.15 (0.63–2.08) | 107 | 0.78 (0.58–1.05) | 20 | 1.27 (0.65–2.48) |
| ≥15.2 | 396 | 81 | 0.91 (0.65–1.27) | 19 | 0.92 (0.50–1.72) | 97 | 0.69 (0.51–0.94) | 18 | 1.09 (0.54–2.19) |
| Trend P-value | 0.57 | 0.88 | 0.01 | 0.99 | |||||
| Homogeneity of trends | P = 0.38 | ||||||||
| Cases sub-grouped by ER/PR/HER2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Average exercise activity (annual MET h/week) | No. of controls | No. of cases | OR (95% CI) | No of cases | OR (95% CI) | No. of cases | OR (95% CI) | No. of cases | OR (95% CI) |
| Cases sub-grouped by ER/PR/HER2 status | |||||||||
| TN | HER2-enriched | ER/PR+/HER2− | ER/PR+/HER2+ | ||||||
| Inactive | 500 | 93 | Referent | 25 | Referent | 165 | Referent | 24 | Referent |
| ≤2.2 | 373 | 52 | 0.78 (0.54–1.13) | 17 | 1.07 (0.56–2.03) | 117 | 0.86 (0.65–1.14) | 22 | 1.20 (0.65–2.20) |
| 2.3–6.6 | 369 | 67 | 0.98 (0.68–1.39) | 20 | 1.20 (0.64–2.24) | 134 | 0.95 (0.72–1.25) | 29 | 1.54 (0.86–2.76) |
| 6.7–15.1 | 374 | 52 | 0.70 (0.48–1.03) | 19 | 1.21 (0.64–2.30) | 121 | 0.81 (0.61–1.08) | 23 | 1.17 (0.63–2.17) |
| ≥15.2 | 396 | 71 | 0.92 (0.64–1.31) | 15 | 0.88 (0.44–1.74) | 107 | 0.70 (0.52–0.94) | 22 | 1.08 (0.58–2.02) |
| Trend P-value | 0.48 | 0.94 | 0.02 | 0.84 | |||||
| Homogeneity of trends | P = 0.52 | ||||||||
OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative. TN, ER−/PR−/HER2−; HER2-enriched, ER−/PR−/HER2+; ER/PR+/HER2−, ER+ or PR+ plus HER2−; ER/PR+/HER2+, ER+ or PR+ plus HER2+.
1
Adjusted for study site, race, education, age, family history of breast cancer, age at menarche, parity, a four-category variable combining menopausal status and hormone therapy use, body mass index, and the duration of oral contraceptive use.